Triple Agonist 30mg Pen (GLP-1 / GIP / Glucagon) – Viogen Pharmaceuticals

Triple Agonist 30mg Pen (GLP-1 / GIP / Glucagon) – Viogen Pharmaceuticals

This is a triple receptor agonist, acting simultaneously on the GLP-1, GIP and glucagon receptors. It follows on from earlier compounds in the incretin class that act on only one or two of these receptors, and in published Phase 2 data it produced the largest weight reductions yet reported for a single injectable agent in its class. This Viogen Pharmaceuticals presentation supplies 30mg in a pre-filled, dial-a-dose pen with 20 needles included, so no reconstitution, no vials and no drawing up is required.

Important – regulatory status: this compound is investigational. It is not approved for sale or medical use by the MHRA, EMA, FDA or any other regulator anywhere in the world. Phase 3 trials for this mechanism are still running. It is supplied here as a research compound and no medical claims are made for it.

Mechanism of Action

This is one of the first agonists in its class to add a glucagon receptor arm to the incretin effect:

• GLP-1 receptor – slows gastric emptying, increases satiety and reduces food intake; the mechanism shared with GLP-1-only agonists
• GIP receptor – improves insulin sensitivity and appears to blunt the nausea associated with GLP-1 activity alone; the additional arm found in dual GIP/GLP-1 agonists
• Glucagon (GCGR) receptor – the distinguishing third arm, increasing energy expenditure and hepatic fat oxidation rather than reducing intake alone

The practical difference is that the first two arms mainly reduce calories consumed, while the glucagon arm raises calories burned. That combination is the accepted explanation for the magnitude of loss seen in trials.

Clinical Data

The key dataset is published 48-week Phase 2 obesity data:

• 12mg weekly – mean weight reduction of approximately 24.2% at 48 weeks
• 8mg weekly – approximately 22.8%
• 4mg weekly – approximately 17.5%
• Placebo – approximately 2.1%
• Weight loss had not plateaued by week 48 in the higher-dose arms

For context, dual GIP/GLP-1 agonists have reported roughly 20–21% over 72 weeks in their own Phase 3 programmes. Phase 2 results are not confirmatory and Phase 3 outcomes for a triple agonist may differ.

Dosage and Titration

This compound has a half-life of roughly six days, which supports once-weekly subcutaneous administration on the same day each week. Titration is not optional – starting high is the single most common cause of people abandoning this class of compound.

• Weeks 1–4: 0.5mg once weekly
• Weeks 5–8: 1mg once weekly
• Weeks 9–12: 2mg once weekly
• Weeks 13–16: 3mg once weekly
• Thereafter: increase in 1mg steps every 4 weeks only if gastrointestinal tolerance is good
• Hold at the lowest dose that is still producing results rather than climbing automatically

This pen dials 0.5mg, 1mg, 1.5mg, 2mg, 2.5mg, 3mg, 3.5mg, 4mg, 4.5mg, 5mg, 5.5mg and 6mg. Trial doses above 6mg are not achievable from a single dose of this device.

Administration

• Route: subcutaneous only – abdomen, thigh or upper arm. Never intramuscular or intravenous
• Rotate the injection site each week to avoid local lipohypertrophy
• Attach a fresh 31g needle for every dose; the pen ships with 20
• Prime the pen before the first use as per the enclosed leaflet
• If a dose is missed and the next is more than 3 days away, take it; otherwise skip and resume the normal schedule

Side Effects

The adverse-event profile in trials was dominated by gastrointestinal effects, dose-dependent and generally worst in the days after a dose increase:

• Common: nausea, vomiting, diarrhoea, constipation, reduced appetite, dyspepsia
• Also reported: a dose-dependent increase in resting heart rate, transient at the doses studied
• Class warnings: pancreatitis and gallbladder events are recognised risks across the incretin class
• Rapid weight loss without adequate protein intake and resistance training costs lean mass as well as fat

Because the glucagon arm increases energy expenditure, hydration and electrolyte intake matter more with this compound than with GLP-1-only agents.

Who Should Not Use It

• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• History of pancreatitis
• Pregnancy, planned pregnancy or breastfeeding
• Type 1 diabetes, or type 2 diabetes on insulin or sulfonylureas without medical supervision – hypoglycaemia risk
• Severe gastrointestinal disease including gastroparesis

Storage

• Store unopened at 2–8°C in a refrigerator. Do not freeze – a frozen peptide is a discarded peptide
• Keep in the outer carton to protect from light
• Once in use, the pen may be kept at room temperature below 30°C for a limited period as stated in the leaflet
• Do not use if the solution is cloudy, discoloured or contains particles

Pack Contents

• 1 x pre-filled Viogen triple agonist pen, 30mg/3mL cartridge
• 20 x 31g 5mm disposable pen needles
• 1 x instruction leaflet
• Verification code inside the carton for authentication against the manufacturer's system

Frequently Asked Questions

How does a triple receptor agonist compare with dual or single-receptor agonists?
This compound adds glucagon receptor agonism on top of the GLP-1 and GIP activity that dual GIP/GLP-1 agonists provide, and on top of the GLP-1 activity that GLP-1-only agonists provide. Phase 2 data suggest greater weight reduction than either earlier mechanism has produced in its own trials, but dual and single-receptor compounds are approved medicines with Phase 3 evidence behind them, and this triple agonist is not.

Is this compound legal in the UK?
It has no marketing authorisation in the UK and is not licensed for human use. It is sold as a research compound only.

How long does one pen last?
That depends entirely on the dose. At the 0.5mg starting dose a 30mg pen covers a long titration period; at 6mg weekly it covers five doses. The cartridge is 30mg in total.

Do I need to reconstitute anything?
No. The pen arrives pre-filled with solution. Attach a needle, dial the dose, inject.

What happens if I stop?
As with every compound in this class, appetite returns and weight regain is expected unless the eating and training habits built during use are maintained.